Skip to main content
. 2017 Mar 2;7:43711. doi: 10.1038/srep43711

Figure 3. Characterization of PF-46396-resistant mutants.

Figure 3

CA-SP1 accumulation assay of (a) HIV-1 clade C K3016 WT, K3016 A1V, I201V and H226Y mutants (b) HIV-1 clade C K3016 WT, K3016 G156E, P157S and P160L mutants (c) HIV-1 clade C K3016 WT, K3016 G225D, A3V and A3T mutants. HEK-293T cells were transfected with HIV-1 clade C clone K3016 WT and indicated K3016 mutants. Cells were treated with PF-46396 (1.0 & 5.0 μM) or with DMSO only. Cell- and virion-associated Gag proteins were detected by western blotting. Positions of Pr55Gag, p41, CA, and CA-SP1 are indicated. Lanes are numbered at the bottom of the gel. Gel images shown here are representative of three independent experiments. Quantification of virion-associated % CA-SP1 relative to total CA + CA-SP1 is presented in the graphs on the right side of each panel. (d) Relative virus release efficiency (VRE) of PF-46396-resistant mutants in the absence and presence of the compound. VRE is calculated as % of [virus-associated CA + CA-SP1]/[total (cell + virus-associated) Gag] relative to K3016 WT from (ac) gel images. Error bars indicate standard deviations from three independent experiments.